Mixomicetes nuevos o interesantes para la flora iberica y Balear. III

Señalamos la presencia de Calomyxa metallica, Clastoderma debaryanum y Dianema harveyi en diferentes localidades peninsulares. De dichas especies, no indicadas hasta el momento para la flora española, comentamos la corologia, ecologia y caracteres diferenciales.

The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.

The GH-2000 and GH-2004 projects have developed a method for detecting GH misuse based on measuring insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP). The objectives were to analyze more samples from elite athletes to improve the reliability of the decision limit estimates, to evaluate whether the existing decision limits needed revision, and to validate further non-radioisotopic assays for these markers. The study included 998 male and 931 female elite athletes. Blood samples were collected according to World Anti-Doping Agency (WADA) guidelines at various sporting events including the 2011 International Association of Athletics Federations (IAAF) World Athletics Championships in Daegu, South Korea. IGF-I was measured by the Immunotech A15729 IGF-I IRMA, the Immunodiagnostic Systems iSYS IGF-I assay and a recently developed mass spectrometry (LC-MS/MS) method. P-III-NP was measured by the Cisbio RIA-gnost P-III-P, Orion UniQ? PIIINP RIA and Siemens ADVIA Centaur P-III-NP assays. The GH-2000 score decision limits were developed using existing statistical techniques. Decision limits were determined using a specificity of 99.99% and an allowance for uncertainty because of the finite sample size. The revised Immunotech IGF-I - Orion P-III-NP assay combination decision limit did not change significantly following the addition of the new samples. The new decision limits are applied to currently available non-radioisotopic assays to measure IGF-I and P-III-NP in elite athletes, which should allow wider flexibility to implement the GH-2000 marker test for GH misuse while providing some resilience against manufacturer withdrawal or change of assays. Copyright © 2015 John Wiley & Sons, Ltd.

La Enfermedad a lo largo de la historia. Un punto de mira entre la biología y la simbología

Las enfermedades tienen sus propios ritmos que se van modificando a lo largo de los siglos; cada sociedad construye su forma de pensar y sentir las enfermedades. La interdependencia entre las condiciones biológicas y sociales de la vida civilizada, ha ocasionado que cada momento histórico viva de forma distinta la enfermedad. El objetivo de este artículo es reflexionar sobre la forma de ver y vivir la enfermedad en Occidente, a lo largo de la historia, centrándonos especialmente en la creencia, surgida a partir del siglo XVIII, que el progreso humano erradicaría la enfermedad. Las raíces de la forma de sentir la enfermedad en el Occidente de inicios del siglo XXI deben buscarse en los orígenes griegos y judeo-cristianos, que se continúan a lo largo de la Edad Media, hasta que con la llegada de la Modernidad se produce un giro desde la búsqueda de la eternidad en el otro mundo, hacia un caminar a la inmortalidad en la tierra. En los inicios del siglo XXI, el hombre post-moderno traslada la crisis de pensamiento vigente al campo de la salud, ello plantean tensiones que se hacen patentes en la forma de vivir y atender la enfermedad

La Enfermedad a lo largo de la historia. Un punto de mira entre la biología y la simbología

Las enfermedades tienen sus propios ritmos que se van modificando a lo largo de los siglos; cada sociedad construye su forma de pensar y sentir las enfermedades. La interdependencia entre las condiciones biológicas y sociales de la vida civilizada, ha ocasionado que cada momento histórico viva de forma distinta la enfermedad. El objetivo de este artículo es reflexionar sobre la forma de ver y vivir la enfermedad en Occidente, a lo largo de la historia, centrándonos especialmente en la creencia, surgida a partir del siglo XVIII, que el progreso humano erradicaría la enfermedad. Las raíces de la forma de sentir la enfermedad en el Occidente de inicios del siglo XXI deben buscarse en los orígenes griegos y judeo-cristianos, que se continúan a lo largo de la Edad Media, hasta que con la llegada de la Modernidad se produce un giro desde la búsqueda de la eternidad en el otro mundo, hacia un caminar a la inmortalidad en la tierra. En los inicios del siglo XXI, el hombre post-moderno traslada la crisis de pensamiento vigente al campo de la salud, ello plantean tensiones que se hacen patentes en la forma de vivir y atender la enfermedad

La circulación de libros desde Europa a Quito en los siglos XVI-XVII

La lectura no es posible sin libro, para que los libros lleguen al lector deben recorrer un largo proceso material y una no menos material circulación desde que se imprimen hasta que llegan a manos u oídos del lector. Atender los circuitos por los cuales llegan a Quito los libros que alimentan el interés de los lectores coloniales, puede resultar un primer paso para precisar las posibilidades reales de adquisición y lectura de libros. La movilidad del libro muestra un universo de relaciones, de tal manera que el libro implica a un buen número de agentes sociales y culturales. Este trabajo se ocupa de las redes comerciales y de intercambio del libro destinado al mercado quiteño a través de la carrera de Indias.

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

Lower incisor dentoalveolar compensation and symphysis dimensions among Class I and III malocclusion patients with different facial vertical skeletal patterns

Objective: To compare lower incisor dentoalveolar compensation and mandible symphysis morphology among Class I and Class III malocclusion patients with different facial vertical skeletal patterns. Materials and Methods: Lower incisor extrusion and inclination, as well as buccal (LA) and lingual (LP) cortex depth, and mandibular symphysis height (LH) were measured in 107 lateral cephalometric x-rays of adult patients without prior orthodontic treatment. In addition, malocclusion type (Class I or III) and facial vertical skeletal pattern were considered. Through a principal component analysis (PCA) related variables were reduced. Simple regression equation and multivariate analyses of variance were also used. Results: Incisor mandibular plane angle (P < .001) and extrusion (P  =  .03) values showed significant differences between the sagittal malocclusion groups. Variations in the mandibular plane have a negative correlation with LA (Class I P  =  .03 and Class III P  =  .01) and a positive correlation with LH (Class I P  =  .01 and Class III P  =  .02) in both groups. Within the Class III group, there was a negative correlation between the mandibular plane and LP (P  =  .02). PCA showed that the tendency toward a long face causes the symphysis to elongate and narrow. In Class III, alveolar narrowing is also found in normal faces. Conclusions: Vertical facial pattern is a significant factor in mandibular symphysis alveolar morphology and lower incisor positioning, both for Class I and Class III patients. Short-faced Class III patients have a widened alveolar bone. However, for long-faced and normal-faced Class III, natural compensation elongates the symphysis and influences lower incisor position.

Integrated regulation of the type III secretion system and other virulence determinants in Ralstonia solanacearum

In many plant and animal bacterial pathogens, the Type III secretion system (TTSS) that directly translocates effector proteins into the eukaryotic host cells is essential for the development of disease. In all species studied, the transcription of the TTSS and most of its effector substrates is tightly regulated by a succession of consecutively activated regulators. However, the whole genetic programme driven by these regulatory cascades is still unknown, especially in bacterial plant pathogens. Here, we have characterised the programme triggered by HrpG, a host-responsive regulator of the TTSS activation cascade in the plant pathogen Ralstonia solanacearum. We show through genome-wide expression analysis that, in addition to the TTSS, HrpG controls the expression of a previously undescribed TTSS-independent pathway that includes a number of other virulence determinants and genes likely involved in adaptation to life in the host. Functional studies revealed that this second pathway co-ordinates the bacterial production of plant cell wall-degrading enzymes, exopolysaccharide, and the phytohormones ethylene and auxin. We provide experimental evidence that these activities contribute to pathogenicity. We also show that the ethylene produced by R. solanacearum is able to modulate the expression of host genes and can therefore interfere with the signalling of plant defence responses. These results provide a new, integrated view of plant bacterial pathogenicity, where a common regulator activates synchronously upon infection the TTSS, other virulence determinants and a number of adaptive functions, which act co-operatively to cause disease.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

BACKGROUND: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted agents such as anti-angiogenic agents (bevacizumab, aflibercept, regorafenib) and anti-epidermal growth factor receptor agents (cetuximab, panitumumab) have become available. Ultimately, given the increasing cost of new active compounds, new strategy trials are needed to define the optimal use and the best sequencing of these agents. Such new clinical trials require alternative endpoints that can capture the effect of several treatment lines and be measured earlier than overall survival to help shorten the duration and reduce the size and cost of trials. METHODS/DESIGN: STRATEGIC-1 is an international, open-label, randomized, multicenter phase III trial designed to determine an optimally personalized treatment sequence of the available treatment modalities in patients with unresectable RAS wild-type mCRC. Two standard treatment strategies are compared: first-line FOLFIRI-cetuximab, followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A) vs. first-line OPTIMOX-bevacizumab, followed by irinotecan-based second-line chemotherapy with bevacizumab, and by an anti-epidermal growth factor receptor monoclonal antibody with or without irinotecan as third-line treatment (Arm B). The primary endpoint is duration of disease control. A total of 500 patients will be randomized in a 1:1 ratio to one of the two treatment strategies. DISCUSSION: The STRATEGIC-1 trial is designed to give global information on the therapeutic sequences in patients with unresectable RAS wild-type mCRC that in turn is likely to have a significant impact on the management of this patient population. The trial is open for inclusion since August 2013. TRIAL REGISTRATION: STRATEGIC-1 is registered at Clinicaltrials.gov: NCT01910610, 23 July, 2013. STRATEGIC-1 is registered at EudraCT-No.: 2013-001928-19, 25 April, 2013.

Figuras III, de Gerard Genette

Borges decía que son clásicos aquellos libros que uno conoce antes de haberlos leído. Quizás en este sentido (sin duda en muchos otros) podemos afirmar que Figuras III, de Gérard Genette ,es un clásico. Se trata, sin embargo, de un libro de lectura lenta y, en ocasiones, confusa que quizás sea necesario resumir y sistematizar. El propósito de esta reseña, claro está, no es sustituir la lectura individual del mismo, sino , en todo caso, como si de una guía de viajes se tratase, introducir y animar a su lectura.

Breve historia de la literatura escéptica

Proponemos el término"literatura escéptica" para referirnos a aquellas obras cuyo tema y convicción fundamental es la incapacidad cognoscitiva del ser humano y sus implicaciones éticas, políticas, religiosas y existenciales. Ciertamente, a cada doctrina o sensibilidad filosófica corresponde, de forma compleja y bilateral, una constelación de rasgos literarios, más o menos constantes, en los diversos ámbitos del estilo, las estructuras narrativas, los temas o los símbolos.

Qui va matar Ramsès III? La resposta és en l'ADN

Egiptòlegs, biòlegs, radiòlegs i patòlegs intervenen en un estudi genètic per reconstruir el gran enigma de com va morir el faraó i quin dels seus fills el va substituir

Centenario de Ferrer Guardia: historia y sociología de la posibilidad

Este año se conmemora el centenario de a ejecución del pedagogo catalán Ferrer Guardia acusado por las autoridades como máximo responsable de la revuelta popular de Barcelona conocida como Semana Trágica. Ferrer Guardia había proyectado en la Escuela Moderna una educación destinada a solucionar los problemas estructurales de la sociedad de su época. Recuperar la memoria de su proyecto educativo nos permite superar la sociología de la educación reproduccionista que es incapaz de ver que hubo escuelas que abogaron por la transformación social. Recobrar a Ferrer Guardia junto a otros personajes que vivieron en su tiempo y que también buscaron soluciones pacíficas ante los conflictos, como Idelfons Cerdá o el poeta Joan Maragall, es plantear la historia como algo no cerrado sino como una posibilidad que desde la sociología y la educación puede ayudarnos en el presente y en el futuro a construir una sociedad mejor.

Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate.

OBJECTIVE: The objective of this study was to compare posttreatment seizure severity in a phase III clinical trial of eslicarbazepine acetate (ESL) as adjunctive treatment of refractory partial-onset seizures. METHODS: The Seizure Severity Questionnaire (SSQ) was administered at baseline and posttreatment. The SSQ total score (TS) and component scores (frequency and helpfulness of warning signs before seizures [BS]; severity and bothersomeness of ictal movement and altered consciousness during seizures [DS]; cognitive, emotional, and physical aspects of postictal recovery after seizures [AS]; and overall severity and bothersomeness [SB]) were calculated for the per-protocol population. Analysis of covariance, adjusted for baseline scores, estimated differences in posttreatment least square means between treatment arms. RESULTS: Out of 547 per-protocol patients, 441 had valid SSQ TS both at baseline and posttreatment. Mean posttreatment TS for ESL 1200mg/day was significantly lower than that for placebo (2.68 vs 3.20, p<0.001), exceeding the minimal clinically important difference (MCID: 0.48). Mean DS, AS, and SB were also significantly lower with ESL 1200mg/day; differences in AS and SB exceeded the MCIDs. The TS, DS, AS, and SB were lower for ESL 800mg/day than for placebo; only SB was significant (p=0.013). For both ESL arms combined versus placebo, mean scores differed significantly for TS (p=0.006), DS (p=0.031), and SB (p=0.001). CONCLUSIONS: Therapeutic ESL doses led to clinically meaningful, dose-dependent reductions in seizure severity, as measured by SSQ scores. CLASSIFICATION OF EVIDENCE: This study presents Class I evidence that adjunctive ESL (800 and 1200mg/day) led to clinically meaningful, dose-dependent seizure severity reductions, measured by the SSQ.

ADHD candidate gene (DRD4 exon III) affects inhibitory control in a healthy sample.

Background Dopamine is believed to be a key neurotransmitter in the development of attention-deficit/ hyperactivity disorder (ADHD). Several recent studies point to an association of the dopamine D4 receptor (DRD4) gene and this condition. More specifically, the 7 repeat variant of a variable number of tandem repeats (VNTR) polymorphism in exon III of this gene is suggested to bear a higher risk for ADHD. In the present study, we investigated the role of this polymorphism in the modulation of neurophysiological correlates of response inhibition (Go/Nogo task) in a healthy, high-functioning sample. Results Homozygous 7 repeat carriers showed a tendency for more accurate behavior in the Go/Nogo task compared to homozygous 4 repeat carriers. Moreover, 7 repeat carriers presented an increased nogo-related theta band response together with a reduced go-related beta decrease. Conclusions These data point to improved cognitive functions and prefrontal control in the 7 repeat carriers, probably due to the D4 receptor's modulatory role in prefrontal areas. The results are discussed with respect to previous behavioral data on this polymorphism and animal studies on the impact of the D4 receptor on cognitive functions.